ArticleHaematologica2022
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.
Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.Blood advances · 2024Trial
- Harnessing Vδ1Frontiers in immunology · 2026Review
- Comparative Preclinical Analysis of Anti-B7-H3 CAR-T Cells Targeting Neuroblastoma.Biomedicines · 2025Article
- A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.Cancer research communications · 2025Article
- Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.Experimental hematology & oncology · 2024Review
- IL-4 drives exhaustion of CD8Nature communications · 2024Article
- Genetically engineering glycolysis in T cells increases their antitumor function.Journal for immunotherapy of cancer · 2024Article
- Review
- Revolutionizing cancer treatment: the emerging potential and potential challenges ofTheranostics · 2024Review
- Current progress in CAR-based therapy for kidney disease.Frontiers in immunology · 2024Review
- Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.Haematologica · 2023Article
- Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland.Biomedicines · 2022Review
- Exhaustion of CAR T cells: potential causes and solutions.Journal of translational medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T-cell based immunotherapy has become a promising treatment mainly for hematological malignancies. Following the major success of CD19-targeted CAR, new potential targets for other malignancies are required. As such, B-cell maturation antigen (BCMA) is an attractive tumor-associated antigen to be targeted in multiple myeloma (MM). Herein, we aimed at assessing the function and optimal configuration of different BCMA-specific CAR, based on the same targeting moiety but with a different hinge and co-stimulatory domain. We compared their function to that of a previously characterized BCMA-CAR used in clinical trials. All constructs were expressed at high levels by primary human T cells and could trigger cytokine production and cytotoxicity upon co-culture with multiple myeloma targets. Nonetheless, critical differences were observed in off-target activation, exhaustion, and activation marker expression and in vivo antitumoral activity mediated by these different constructs. Interestingly, we noted that CD8-based hinge, combined with a 4-1BB intracellular domain, proved superior compared to IgG4-connecting regions, and/or a CD28-signaling moiety respectively. Overall, this study emphasizes the influence of CAR primary structure on its function and led to the identification of a highly efficient BCMA-specific CAR, namely H8BB, which displayed superior anti-tumoral activity both in vitro and long-term in vivo efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.